Vytan

Vytan

valsartan

Manufacturer:

Duopharma Manufacturing (Bangi)

Distributor:

Duopharma Marketing
Concise Prescribing Info
Contents
Valsartan
Indications/Uses
Dosage/Direction for Use
HTN 80 or 160 mg once daily, may be increased to 320 mg once daily or diuretic may be added. Heart failure Initially 40 mg bd, up-titrated to 80 & 160 mg bd as tolerated. Max: 320 mg daily in divided doses. Post MI Initially 20 mg bd, up-titrated to max: 160 mg bd as tolerated.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Concomitant use w/ aliskiren in patients w/ type 2 DM. Severe hepatic impairment; biliary cirrhosis, cholestasis. Pregnancy.
Special Precautions
Discontinue use & not to be re-administered in patients w/ history of angioedema. Not to be used in primary hyperaldosteronism. Not recommended in dual blockade of renin-angiotensin-aldosterone system. Risk of hypotension in Na &/or vol-depleted patients; bilateral renal artery stenosis or stenosis to solitary kidney; aortic or mitral stenosis, hypertrophic obstructive cardiomyopathy; severe CHF. Regularly monitor K levels, renal function, electrolytes & BP. Galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption. Not recommended in concomitant use w/ K supplements, K-sparing diuretics, K-containing salt substitutes or other agents increasing K levels eg, heparin. Kidney transplantation; severe renal impairment (CrCl <10 mL/min), patients undergoing dialysis. Mild to moderate hepatic impairment w/o cholestasis. Not to be used during 2nd & 3rd trimesters of pregnancy. Not recommended during lactation. Childn & adolescents <18 yr.
Adverse Reactions
Dizziness, postural dizziness; hypotension, orthostatic hypotension; renal failure & impairment.
Drug Interactions
Increased lithium conc & toxicity. Increased K levels w/ K supplements, K-sparing diuretics, K-containing salt substitutes or other substances increasing K levels. Attenuated antihypertensive effect w/ NSAIDs including selective COX-2 inhibitors, acetylsalicylic acid.
ATC Classification
C09CA03 - valsartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Vytan FC tab 160 mg
Packing/Price
10 × 10's;3 × 10's
Form
Vytan FC tab 80 mg
Packing/Price
10 × 10's;3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in